HTG Molecular Diagnostics Announces Closing of a $10 Million Public Offering

  HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a life science company advancing precision medicine through its innovative transcriptome-wide profiling and advanced medicinal chemistry technology, today announced the closing of its previously announced public offering of an aggregate of 1,290,322 shares of its common stock (or pre-funded warrants in lieu thereof), Series A-1 warrants to purchase up to 1,290,322 shares of common stock and Series A-2 warrants to purchase 1,290,322 shares of common stock, at a combined public offering price of $7.75 per share (or pre-funded warrant) and accompanying warrants. The Series A-1 warrants have an exercise price of $7.50 per share, are immediately exercisable and will expire five years from the date of issuance, and the Series A-2 warrants have an exercise price of $7.50 per share, are immediately exercisable and will expire twenty-four months from the date of issuance.

H.C. Wainwright & Co. acted as the exclusive placement agent for the offering.

The gross proceeds from the offering, before deducting the placement agent's fees and other offering expenses, are approximately $10.0 million. The Company intends to use the net proceeds from this offering for general corporate purposes, which may include research and development expenses, clinical trial expenses, capital expenditures and working capital.

https://finance.yahoo.com/news/htg-molecular-diagnostics-announces-closing-210500784.html